Related Experiment Videos
Toxicity antagonists in cancer therapy
1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Abstract:
Modern cancer therapy produces substantial acute and chronic toxicity which impairs quality of life and limits the effectiveness of treatment. Recent clinical and laboratory data suggest that repair of treatment-related injury is a multiphase and continuous process providing multiple opportunities for pharmacologic intervention. A host of agents (toxicity antagonists) are under development that modulate normal tissue response or interfere with mechanisms of toxicity. Although significant challenges remain, the routine application of such agents promises to substantially reduce treatment related morbidity and potentially allow treatment intensification in high-risk disease.
Insights
Cancer treatments cause significant toxicity, impacting patient quality of life. New agents aim to reduce this harm, potentially allowing for more intensive cancer therapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cancer therapies cause acute and chronic toxicities, diminishing patient quality of life and treatment efficacy.
- Treatment-related injuries involve complex repair processes offering therapeutic intervention windows.
Purpose of the Study:
- To explore the development of agents (toxicity antagonists) designed to mitigate cancer treatment toxicity.
- To assess the potential of these agents in reducing treatment-related morbidity and enabling treatment intensification.
Main Methods:
- Review of recent clinical and laboratory data on treatment-related injury and repair mechanisms.
- Analysis of agents under development that modulate normal tissue response or interfere with toxicity pathways.
Main Results:
- Pharmacologic interventions targeting toxicity are under development.
- These agents show promise in modulating normal tissue responses to cancer therapy.
Conclusions:
- Developing toxicity antagonists offers a promising strategy to reduce cancer treatment morbidity.
- Successful application of these agents could allow for intensified treatment regimens in high-risk cancers.